Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- A diagnosis of small cell lung cancer (SCLC) confirmed through laboratory testing of tissue or cell samples.
- A specialist team (multidisciplinary tumor board) has decided that a combination of chemotherapy and immunotherapy is the appropriate first treatment.
- The person is able to attend and complete the follow-up visits required by the study.
- The person is 18 years of age or older.
- The person is enrolled in a French social security scheme.
- The person is being treated in the Thoracic Oncology department at either Cochin Hospital or HEGP.
- The person is able to understand the participant information sheet provided by the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- The person has declined to participate after receiving the information sheet.
- The person is not sufficiently proficient in the French language.
- The person is under a legal protection measure, such as guardianship or curatorship, or is deprived of liberty.
- The person is currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Simon Garinet, Assistance Publique - Hôpitaux de Paris
Phone: +33156095982
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
To evaluate the evolution of the four molecular subtypes (SCLC-A, SCLC-N, SCLC-P, and SCLC-I) during first-line chemo-immunotherapy using epigenomic analyses performed on plasma samples from patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.